| 利用者成果(英) |
|
22099
Dini A, Barker H, Piki E, Sharma S, Raivola J, Murumägi A, Ungureanu D.
A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery.
Nat Chem Biol
2024
PubMed ID: 39482470
DOI: 10.1038/s41589-024-01761-8
|
|
21426
Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N, Shozu K, Asada K, Kaneko S, Yoshida H, Kato T, Nakayama K, Saloura V, Kyo S, Hamamoto R.
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Exp Mol Med
2023
PubMed ID: 37779141
DOI: 10.1038/s12276-023-01090-1
|
|
21483
Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Osuga Y.
Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma.
Sci Rep
2023
13(1):20292
PubMed ID: 37985723
DOI: 10.1038/s41598-023-47637-0
|
|
20521
Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R.
The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Commun Biol
2022
5(1):39
PubMed ID: 35017636
DOI: 10.1038/s42003-021-02992-4
|
|
20800
Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W, Li L.
Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.
Hum Cell
2022
PubMed ID: 35907138
DOI: 10.1007/s13577-022-00748-8
|
|
20211
Oyama Y, Shigeta S, Tokunaga H, Tsuji K, Ishibashi M, Shibuya Y, Shimada M, Yasuda J, Yaegashi N.
CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
PLoS One
2021
16(6):e0251079
PubMed ID: 34161330
DOI: 10.1371/journal.pone.0251079
|
|
13066
Álvarez-Quilón A, Wojtaszek JL, Mathieu MC, Patel T, Appel CD, Hustedt N, Rossi SE, Wallace BD, Setiaputra D, Adam S, Ohashi Y, Melo H, Cho T, Gervais C, Muñoz IM, Grazzini E, Young JTF, Rouse J, Zinda M, Williams RS, Durocher D.
Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.
Mol Cell
2020
PubMed ID: 32516598
DOI: 10.1016/j.molcel.2020.05.021
|
|
13262
Escalona RM, Bilandzic M, Western P, Kadife E, Kannourakis G, Findlay JK, Ahmed N.
TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
BMC Cancer
2020
PubMed ID: 33023532
DOI: 10.1186/s12885-020-07274-6
|
|
13385
Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Yang A, Kalekar RL, Krill-Burger JM, Dharia NV, Kugener G, Kalfon J, Yuan C, Dumont N, Gonzalez A, Abdusamad M, Li YY, Spurr LF, Wu WW, Durbin AD, Wolpin BM, Piccioni F, Root DE, Boehm JS, Cherniack AD, Tsherniak A, Hong AL, Hahn WC, Stegmaier K, Golub TR, Vazquez F, Aguirre AJ.
Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.
Cell Rep
2020
PubMed ID: 33326793
DOI: 10.1016/j.celrep.2020.108493
|
|
13387
Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T.
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Biomolecules
2020
PubMed ID: 33339442
DOI: 10.3390/biom10121686
|
|
13700
Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, Yamashita Y, Ito K, Yamada H, Shima H, Yaegashi N, Tanuma N.
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer
FEBS Lett
2020
594(9):1379-1388
PubMed ID: 31950503
DOI: 10.1002/1873-3468.13736
|
|
11501
Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Biochem. Biophys. Res. Commun.
2019
PubMed ID: 30955858
DOI: 10.1016/j.bbrc.2019.03.155
|
|
11511
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature
2019
PubMed ID: 30971826
DOI: 10.1038/s41586-019-1103-9
|
|
13420
Hamedi, Bahareh
Anti-cancer effects of n-3 long-chain polyunsaturated fatty acids (LCPUFA) on ovarian cancer growth in vitro and in vivo
2019
DOI: 10.7939/r3-44r2-2q82
|
|
10833
Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, Sugiyama A, Mandai M, Konishi I, Matsumura N.
Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation.
Nat Commun
2018
9:1685
PubMed ID: 29703902
DOI: 10.1038/s41467-018-03966-7
|
|
10676
Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.
Sci Rep
2017
7:18086
PubMed ID: 29273809
DOI: 10.1038/s41598-017-17329-7
|
|
9659
Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich
Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Mol Cancer Ther
2017
16(5):850-860
PubMed ID: 28292935
DOI: 10.1158/1535-7163.MCT-16-0678
|
|
14252
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification
Int J Oncol
2017
50(1):129-140.
PubMed ID: 27922671
DOI: 10.3892/ijo.2016.3786
|
|
15031
Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.
Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma
Int J Oncol
2015
46(4):1573-81
PubMed ID: 25633807
DOI: 10.3892/ijo.2015.2858
|
|
9658
Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii
Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
PLoS One
2014
9(2):e87220
PubMed ID: 24504419
DOI: 10.1371/journal.pone.0087220
|
|
15801
Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A, Park J, Aoki D, Kawakami Y.
Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor
Br J Cancer
2014
110(12):2965-74
PubMed ID: 24867687
DOI: 10.1038/bjc.2014.251
|
|
9669
Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa
Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells
Int J Oncol
2013
43(1):63-71
PubMed ID: 23670532
DOI: 10.3892/ijo.2013.1935
|
|
15560
Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.
Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
Cancer Sci
2008
99:2365-72
PubMed ID: 19032364
DOI: 10.1111/j.1349-7006.2008.00988.x
|
|
2934
Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo
Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.
Clin Cancer Res
2004
10:2687-93
PubMed ID: 15102672
DOI: 10.1158/1078-0432.ccr-03-0510
|
|
3094
Kaneda, Atsushi, Wakazono, Kuniko, Tsukamoto, Tetsuya, Watanabe, Naoko, Yagi, Yukiko, Tatematsu, Masae, Kaminishi, Michio, Sugimura, Takashi, Ushijima, Toshikazu
Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers.
Cancer Res
2004
64:6410-5
PubMed ID: 15374948
DOI: 10.1158/0008-5472.CAN-04-1543
|
|
3796
Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.
Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.
Int J Cancer
2003
107(1):53-9
PubMed ID: 12925956
DOI: 10.1002/ijc.11348
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
